Society of Hematologic Oncology

Society of Hematologic Oncology SOHO is the only global society dedicated to the research & treatment of hematologic malignancies. Join SOHO for FREE today at soho.click/join.

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. SOHO is led by a Board of Directors with six vot

ing members. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively.

“Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Fifth Annual Meeting is scheduled for September 13-16, 2017 at the Westin Galleria and Oaks in Houston, Texas. The society expects more than 1,000 physicians and related professionals to attend the 3.5-day event. (go to soho2017.com for more information and registration).

Watch our interview with Dr. Andrew Kuykendall on the RALLY-MF trial from
06/23/2026

Watch our interview with Dr. Andrew Kuykendall on the RALLY-MF trial from

https://youtu.be/hJ9ApvP62ac?is=N_xmsYKDd8NWZM7v Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses updated data from the phase 2 RALLY-MF trial. The trial evaluated DISC-0974 in patients with myelofibrosis and anemia. DISC-0974 is a first-in-class monoclonal antibody d...

FDA grants fast track designation to STX-0712 in relapsed or refractory CMML
06/17/2026

FDA grants fast track designation to STX-0712 in relapsed or refractory CMML

The US Food and Drug Administration has granted fast track designation to the investigation therapy STX-0712 for the treatment of patients with relapsed or refractory chronic myelomonocytic leukemia. STX-0712 is a CyTAC™ (cytotoxicity targeting chimera) targeting the the CCR2 receptor, highly expr...

Which AML patients get lasting benefit from olutasidenib?
06/09/2026

Which AML patients get lasting benefit from olutasidenib?

Participants with relapsed rather than refractory AML, as well as females, were more likely to get a durable response from the oral IDH1 inhibitor olutasidenib (Rezlidhia), according to a new analysis of pivotal trial data. The drug was evaluated in a phase II registrational study in IDH1-mutated re...

06/09/2026

Join our regional partners in Kuwait for the LLS & SOHO Joint Meeting 2026: Controversies in Hematological Malignancies.

Register here: quotehubkw.com/chm26/

Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials
06/08/2026

Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials

Anitocabtagene autoleucel (anito-cel), an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, was successfully manufactured for the majority of participants with relapsed or refractory or newly diagnosed multiple myeloma in the iMMagine-3 and GEM-AnitoFIRST trials, according to a poster presen...

SOHO will be at  ! Visit us at our booth to learn about our great programs and how you can be involved in the society. L...
06/06/2026

SOHO will be at ! Visit us at our booth to learn about our great programs and how you can be involved in the society. Learn more at sohoonline.org.

Anthony Goldstone built a transplant program. It started in a broom cupboard.
06/04/2026

Anthony Goldstone built a transplant program. It started in a broom cupboard.

Not many haematologists can say their clinical journey began in a broom cupboard. Anthony Goldstone can. “Starting with a single patient in a broom cupboard—almost literally—we built a world-ranked programme that has treated thousands from across the UK and around the world,” he said. Prof. ...

Frontline tafasitamab, lenalidomide plus R-CHOP improves outcomes in B-cell lymphomas
06/03/2026

Frontline tafasitamab, lenalidomide plus R-CHOP improves outcomes in B-cell lymphomas

Tafasitamab plus lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) improved progression-free survival (PFS) compared with R-CHOP alone and had manageable safety for patients with aggressive B-cell lymphomas in the phase 3 frontMIND study, according to a presentation at the 2026 ASCO Annual Meeting. The fro...

Addition of ibrutinib to R-da-EPOCH in HIV-related DLBCL may improve survival outcomes
06/01/2026

Addition of ibrutinib to R-da-EPOCH in HIV-related DLBCL may improve survival outcomes

A study presented by Ida Wong-Sefidan, MD, of the University of California, San Diego, and colleagues at the 2026 ASCO Annual Meeting found that adding ibrutinib to R-da-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) for patients with HIV-related d...

05/31/2026

Early registration ends June 10 for . Register today at soho.click/register.

Address

The Woodlands, TX
77393

Opening Hours

Monday 8am - 6pm
Tuesday 8am - 6pm
Wednesday 8am - 6pm
Thursday 8am - 6pm
Friday 8am - 6pm

Telephone

+12813647387

Alerts

Be the first to know and let us send you an email when Society of Hematologic Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Society of Hematologic Oncology:

Featured

Share